Why Peptides Are Not Orally Bioavailable
Three obstacles in series: gastric acid and pepsin, pancreatic proteases, and an epithelium sealed by tight junctions. Each one alone would be enough.
Peptides are made of the same amino acids as dietary protein, which is digested and absorbed perfectly well. Yet peptide bioavailability by the oral route is typically well under one per cent. The reason is not one obstacle but three, arranged in series.
Obstacle one: the stomach
Gastric fluid sits around pH 1.5 to 3.5. That is acidic enough to drive hydrolysis of peptide bonds directly, and particularly aggressive at Asp-Pro and Asp-Gly sequences. Pepsin, active in exactly that pH range, cleaves preferentially next to aromatic residues — phenylalanine, tryptophan, tyrosine.
A peptide with aromatic residues arriving in the stomach is a substrate, not a passenger.
Obstacle two: intestinal proteases
What survives the stomach meets pancreatic enzymes in the small intestine, each with its own specificity:
- Trypsin — cleaves after lysine and arginine
- Chymotrypsin — cleaves after aromatic residues
- Elastase — cleaves after small residues: alanine, glycine, valine
- Carboxypeptidases — remove residues from the C-terminal end
Between them these cover most of the amino acid alphabet. The brush border adds aminopeptidases and dipeptidyl peptidases on the enterocyte surface, so even a peptide reaching the intestinal wall intact meets another enzyme layer before it can cross.
Obstacle three: the epithelium itself
Suppose a peptide survives both. It still has to cross a cell layer sealed by tight junctions.
- Paracellular — between cells. Tight junctions restrict this to roughly 10 Å; a peptide above about 500 Da does not fit.
- Transcellular — through cells. Requires crossing two lipid membranes, which a charged, hydrophilic molecule does poorly.
- Carrier-mediated — the exception. The PepT1 transporter carries di- and tripeptides actively, which is how dietary protein is absorbed and why very short peptides such as KPV have a route the others lack.
And anything absorbed enters the portal vein and passes through the liver before reaching systemic circulation, where further metabolism removes more.
Why this shapes the entire field
The three-obstacle problem explains a great deal about how peptides are studied and formulated:
- Parenteral routes dominate research protocols because they bypass all three.
- Very short peptides are a special case. Di- and tripeptides have both a transporter and less enzymatic surface area, which is why PepT1-mediated uptake appears repeatedly in tripeptide literature.
- Oral formulation is an engineering problem, not a chemistry one. The one commercially successful oral peptide of this class pairs the molecule with a permeation enhancer — SNAC — and even then bioavailability is around one per cent. The enhancer raises local pH and increases membrane permeability transiently.
- Protease resistance alone is not enough. A peptide engineered to resist DPP-4 still faces trypsin, chymotrypsin, and the epithelium.
The practical point for laboratory work
Route of administration is not an incidental protocol detail — it is often the dominant variable in whether a peptide reaches its target at all. A compound with well-documented activity in a cell-based assay may show nothing in an oral model for reasons that have nothing to do with the compound.
Our article on half-life engineering covers the modifications that address enzymatic degradation, and the sequence guide covers how to spot the cleavage sites in a sequence.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.